C
Claus-Peter Schneider
Publications - 12
Citations - 340
Claus-Peter Schneider is an academic researcher. The author has contributed to research in topics: Carboplatin & Chemotherapy. The author has an hindex of 7, co-authored 11 publications receiving 318 citations.
Papers
More filters
Journal ArticleDOI
Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Small-Cell Lung Cancer
Suresh S. Ramalingam,David R. Spigel,David Y. Chen,Martin Steins,Jeffrey A. Engelman,Claus-Peter Schneider,Silvia Novello,Wilfried Eberhardt,Lucio Crinò,Kai Habben,Lian Liu,Pasi A. Jänne,Carrie Brownstein,Martin Reck +13 more
TL;DR: The combination of R1507 with erlotinib did not provide PFS or survival advantage over erlot inib alone in an unselected group of patients with advanced NSCLC, and predictive biomarkers are essential for further development of combined inhibition of IGF-1R and EGFR.
Journal ArticleDOI
Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)
Janessa Laskin,Lucio Crinò,Enriqueta Felip,Fabio Franke,Vera Gorbunova,Harry J.M. Groen,Guo-liang Jiang,Martin Reck,Claus-Peter Schneider +8 more
TL;DR: Patients older than 65 years with nonsquamous NSCLC derive a similar clinical benefit from first-line bevacizumab-based therapy as their younger counterparts and do not experience increased toxicity.
Journal ArticleDOI
A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.
Wolfgang Schuette,Thomas Blankenburg,Kathrin Lauerwald,Jens Schreiber,Ines Bork,Bettina Wollschlaeger,Dorothea Treutler,Claus-Peter Schneider,Reiner Bonnet +8 more
TL;DR: The combination of gemcitabine and oxaliplatin was shown to be active in malignant pleural mesothelioma and to exhibit tolerable toxicity in an outpatient setting.
Journal ArticleDOI
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
Suresh S. Ramalingam,Jeffrey Crawford,A. Chang,Christian Manegold,Roman Perez-Soler,J.-Y. Douillard,Nick Thatcher,Fabrice Barlesi,Taofeek K. Owonikoko,Y. Wang,P. Pultar,J. Zhu,R. Malik,Giuseppe Giaccone,Stephen Della-Fiorentina,Stephen Begbie,Ross Jennens,J. Dass,K. Pittman,N. Ivanova,T. Koynova,Petar Petrov,A. Tomova,V. Tzekova,Félix Couture,V. Hirsh,R. Burkes,R. Sangha,M. Ambrus,T. Janaskova,J. Musil,J. Novotny,P. Zatloukal,J. Jakesova,K. Klenha,J. Roubec,J. Vanasek,J. Fayette,J. Bennouna-Louridi,Christos Chouaid,Julien Mazieres,H. Vallerand,Gilles Robinet,Pierre-Jean Souquet,D. Spaeth,Roland Schott,Hervé Lena,Y. Martinet,C. El Kouri,N. Baize,Arnaud Scherpereel,Olivier Molinier,F. Fuchs,K. M. Josten,Norbert Marschner,Folker Schneller,T. Overbeck,Michael Thomas,J. von Pawel,Martin Reck,Wolfgang Schuette,V. Hagen,Claus-Peter Schneider,Vassilis Georgoulias,I. Varthalitis,K. Zarogoulidis,Kostas N. Syrigos,Christos Papandreou,C. Bocskei,Eszter Csánky,E. Juhasz,György Losonczy,Z. Mark,I. Molnar,Z. Papai-Szekely,S. Tehenes,I. Vinkler,S. Almel,A. Bakshi,S. Bondarde,A. Maru,A. Pathak,R. M. Pedapenki,K. Prasad,S. V S S Prasad,N. Kilara,D. Gorijavolu,C. D. Deshmukh,Shinu John,L. M. Sharma,Domenico Amoroso,Emilio Bajetta,P. Bidoli,Andrea Bonetti,F. De Marinis,Michele Maio,Rodolfo Passalacqua,Stefano Cascinu,Alessandra Bearz,M. Bitina,A. Brize,G. Purkalne,M. Skrodele,A. A. Baba,K. Ratnavelu,M. H. Saw,M. C. Samson-Fernando,G. E. Ladrera,Jacek Jassem,P. Koralewski,Piotr Serwatowski,Maciej Krzakowski,C. Cebotaru,D. Filip,D. E. Ganea-Motan,C. H. Ianuli,I. G. Manolescu,A. Udrea,O. Burdaeva,M. Byakhov,A. Filippov,S. Lazarev,I. Mosin,Sergey Orlov,D. Udovitsa,A. Khorinko,S. Protsenko,H. L. Lim,Y. O. Tan,E. H. Tan,R. Bastus Piulats,J. Garcia-Foncillas,Javier Valdivia,J. de Castro,M. Domine Gomez,S. W. Kim,J. S. Lee,H. K. Kim,S. W. Shin,D. W. Kim,Y. C. Kim,K. C. Park,C. S. Chang,G. C. Chang,Y. G. Goan,W. C. Su,C. M. Tsai,H. P. Kuo,Mustafa Benekli,Gokhan Demir,Erhan Gokmen,Alper Sevinc,Missak Haigentz,Manyoo Agarwal,S. Pandit,R. Araujo,N. Vrindavanam,Philip Bonomi,A. Berg,James L. Wade,R. Bloom,B. Amin,R. Camidge,D. Hill,M. Rarick,Patrick J. Flynn,L. Klein,K. Lo Russo,M. Neubauer,P. Richards,R. Ruxer,M. Savin,D. Weckstein,R. Rosenberg,T. Whittaker,Donald A. Richards,William R. Berry,Christian H. Ottensmeier,Adam Dangoor,Nicola Steele,Yvonne Summers,E. Rankin,K. Rowley,S. Giridharan,H. Kristeleit,C. Humber,Paul D. Taylor +186 more
TL;DR: There was no improvement in efficacy with talactoferrin alfa in patients with advanced NSCLC whose disease had failed two or more prior regimens and the safety profiles were comparable between arms.
Journal ArticleDOI
Randomized Phase II Study of Ixabepilone or Paclitaxel Plus Carboplatin in Patients With Non–Small-Cell Lung Cancer Prospectively Stratified by Beta-3 Tubulin Status
Martin J. Edelman,Claus-Peter Schneider,Chun-Ming Tsai,Heung-Tae Kim,Elisabeth Quoix,Alexander Luft,Remigiusz Kaleta,Pralay Mukhopadhyay,Ovidiu C. Trifan,Laura Whitaker,Martin Reck +10 more
TL;DR: A randomized phase II study evaluated Ixabepilone-based chemotherapy in stage IIIb/IV non-small-cell lung cancer (NSCLC) treated with tubulin-inhibiting chemotherapy as discussed by the authors.